Arcus Biosciences (RCUS) Cash & Equivalents (2017 - 2026)

Arcus Biosciences' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $201.0 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 4.69% year-over-year to $201.0 million in Q1 2026; TTM through Mar 2026 was $201.0 million, a 4.69% increase from a year earlier, with the FY2025 full-year figure at $222.0 million, up 48.0% from the prior year.
• Cash & Equivalents eased to $201.0 million in Q1 2026 per RCUS's latest filing, from $222.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $549.0 million in Q1 2022 and bottomed at $127.0 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $206.0 million (2022), against an average of $224.6 million.
• Across the five-year window, Cash & Equivalents sank 56.65% in 2023 and soared 58.97% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $206.0 million in 2022, then tumbled by 38.35% to $127.0 million in 2023, then rose by 18.11% to $150.0 million in 2024, then soared by 48.0% to $222.0 million in 2025, then slipped by 9.46% to $201.0 million in 2026.
• Per Business Quant, the three latest RCUS Cash & Equivalents figures stand at $201.0 million (Q1 2026), $222.0 million (Q4 2025), and $238.0 million (Q3 2025).